These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 9338470)
21. The levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinase-9 but not promatrix metalloproteinase-2 activation. Paju A; Sorsa T; Tervahartiala T; Koivunen E; Haglund C; Leminen A; Wahlström T; Salo T; Stenman UH Br J Cancer; 2001 May; 84(10):1363-71. PubMed ID: 11355948 [TBL] [Abstract][Full Text] [Related]
22. Regulation of gelatinase activity in mice with targeted inactivation of components of the plasminogen/plasmin system. Lijnen HR; Silence J; Lemmens G; Frederix L; Collen D Thromb Haemost; 1998 Jun; 79(6):1171-6. PubMed ID: 9657444 [TBL] [Abstract][Full Text] [Related]
23. Expression of matrix metalloproteinases and related tissue inhibitors in the cyst fluids of ovarian mucinous neoplasms. Furuya M; Ishikura H; Kawarada Y; Ogawa Y; Sakuragi N; Fujimoto S; Yoshiki T Gynecol Oncol; 2000 Aug; 78(2):106-12. PubMed ID: 10926788 [TBL] [Abstract][Full Text] [Related]
24. Platelet-activating factor induces the expression of metalloproteinases-1 and -9, but not -2 or -3, in the corneal epithelium. Tao Y; Bazan HE; Bazan NG Invest Ophthalmol Vis Sci; 1995 Feb; 36(2):345-54. PubMed ID: 7843905 [TBL] [Abstract][Full Text] [Related]
26. Expression and role of matrix metalloproteinases MMP-2 and MMP-9 in human spinal column tumors. Gokaslan ZL; Chintala SK; York JE; Boyapati V; Jasti S; Sawaya R; Fuller G; Wildrick DM; Nicolson GL; Rao JS Clin Exp Metastasis; 1998 Nov; 16(8):721-8. PubMed ID: 10211985 [TBL] [Abstract][Full Text] [Related]
27. Regulation of matrix metalloproteinases (MMP-2, -3, -9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption. Kusano K; Miyaura C; Inada M; Tamura T; Ito A; Nagase H; Kamoi K; Suda T Endocrinology; 1998 Mar; 139(3):1338-45. PubMed ID: 9492070 [TBL] [Abstract][Full Text] [Related]
28. Production of matrix metalloproteinases at the bone-implant interface in loose total hip replacements. Yokohama Y; Matsumoto T; Hirakawa M; Kuroki Y; Fujimoto N; Imai K; Okada Y Lab Invest; 1995 Dec; 73(6):899-911. PubMed ID: 8558853 [TBL] [Abstract][Full Text] [Related]
29. Differentiation of human osteoblastic cells in culture: modulation of proteases by extracellular matrix and tumor necrosis factor-alpha. Panagakos FS; Kumar S Inflammation; 1995 Aug; 19(4):423-43. PubMed ID: 7558248 [TBL] [Abstract][Full Text] [Related]
30. Lung alveolar epithelial cells synthesize interstitial collagenase and gelatinases A and B in vitro. Pardo A; Ridge K; Uhal B; Sznajder JI; Selman M Int J Biochem Cell Biol; 1997 Jun; 29(6):901-10. PubMed ID: 9304805 [TBL] [Abstract][Full Text] [Related]
31. Characterization of extracellular matrix-degrading proteinase and its inhibitor in gynecologic cancer tissues with clinically different metastatic form. Tamakoshi K; Kikkawa F; Nawa A; Ishikawa H; Mizuno K; Tamakoshi A; Yamagata S; Suganuma N; Tomoda Y Cancer; 1995 Dec; 76(12):2565-71. PubMed ID: 8625086 [TBL] [Abstract][Full Text] [Related]
32. Activation of tumor cell matrix metalloproteinase-2 by neutrophil proteinases requires expression of membrane-type 1 matrix metalloproteinase. Schwartz JD; Shamamian P; Monea S; Whiting D; Marcus SG; Galloway AC; Mignatti P Surgery; 1998 Aug; 124(2):232-8. PubMed ID: 9706143 [TBL] [Abstract][Full Text] [Related]
33. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes. Ries C; Loher F; Zang C; Ismair MG; Petrides PE Clin Cancer Res; 1999 May; 5(5):1115-24. PubMed ID: 10353746 [TBL] [Abstract][Full Text] [Related]
34. Temporal expression of extracellular matrix metalloproteinases and tissue plasminogen activator in the development of collateral vessels in the canine model of coronary occlusion. Tyagi SC; Kumar S; Cassatt S; Parker JL Can J Physiol Pharmacol; 1996 Aug; 74(8):983-95. PubMed ID: 8960389 [TBL] [Abstract][Full Text] [Related]
35. Analysis of matrix metalloproteinases and related tissue inhibitors in cystic fluids of ovarian tumors. Furuya M Hokkaido Igaku Zasshi; 1999 Mar; 74(2):145-55. PubMed ID: 10386163 [TBL] [Abstract][Full Text] [Related]
36. Characterization of matrix-degrading proteinases and their inhibitors secreted by human gynecological carcinoma cells. Miyagi E; Yasumitsu H; Hirahara F; Minaguchi H; Koshikawa N; Miyazaki K; Umeda M Jpn J Cancer Res; 1995 Jun; 86(6):568-76. PubMed ID: 7622422 [TBL] [Abstract][Full Text] [Related]
37. Mouse trophoblastic cell lines: II--Relationship between invasive potential and proteases. Sharma RK In Vivo; 1998; 12(2):209-17. PubMed ID: 9627804 [TBL] [Abstract][Full Text] [Related]
38. Expression of matrix metalloproteinase 2 (MMP-2), membrane-type 1 MMP and tissue inhibitor of metalloproteinase 2 and activation of proMMP-2 in pancreatic duct adenocarcinomas in hamsters treated with N-nitrosobis(2-oxopropyl)amine. Iki K; Tsutsumi M; Kido A; Sakitani H; Takahama M; Yoshimoto M; Motoyama M; Tatsumi K; Tsunoda T; Konishi Y Carcinogenesis; 1999 Jul; 20(7):1323-9. PubMed ID: 10383907 [TBL] [Abstract][Full Text] [Related]
39. Cytokines stimulate matrix metalloproteinase production by human pulp cells during long-term culture. O'Boskey FJ; Panagakos FS J Endod; 1998 Jan; 24(1):7-10. PubMed ID: 9487857 [TBL] [Abstract][Full Text] [Related]
40. Plasminogen fragmentation and increased production of extracellular matrix-degrading proteinases are associated with serous epithelial ovarian cancer progression. Murthi P; Barker G; Nowell CJ; Rice GE; Baker MS; Kalionis B; Quinn MA Gynecol Oncol; 2004 Jan; 92(1):80-8. PubMed ID: 14751142 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]